Vo AA - Search Results

1

Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab.

Vo AA, Wechsler EA, Wang J, Peng A, Toyoda M, Lukovsky M, Reinsmoen N, Jordan SC. Vo AA, et al. Am J Transplant. 2008 Jan;8(1):144-9. doi: 10.1111/j.1600-6143.2007.02017.x. Epub 2007 Oct 31. Am J Transplant. 2008. PMID: 17973966 Free article.

2

Treatment of parvovirus B-19 (PV B-19) infection allows for successful kidney transplantation without disease recurrence.

Barsoum NR, Bunnapradist S, Mougdil A, Toyoda M, Vo A, Jordan SC. Barsoum NR, et al. Am J Transplant. 2002 May;2(5):425-8. doi: 10.1034/j.1600-6143.2002.20505.x. Am J Transplant. 2002. PMID: 12123207 Free article.

3

Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction.

Jordan SC, Vo A, Bunnapradist S, Toyoda M, Kamil E. Jordan SC, et al. Am J Transplant. 2002 Aug;2(7):671-3. doi: 10.1034/j.1600-6143.2002.20714.x. Am J Transplant. 2002. PMID: 12201370 Free article.

4

Posttransplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation.

Bunnapradist S, Vo A, Toyoda M, Alsabeh R, Lockhart C, Puliyanda D, Jordan SC. Bunnapradist S, et al. Transplantation. 2002 Dec 15;74(11):1648-51. doi: 10.1097/00007890-200212150-00029. Transplantation. 2002. PMID: 12490805

5

Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients.

Jordan SC, Vo A, Bunnapradist S, Toyoda M, Peng A, Puliyanda D, Kamil E, Tyan D. Jordan SC, et al. Transplantation. 2003 Aug 27;76(4):631-6. doi: 10.1097/01.TP.0000080685.31697.FC. Transplantation. 2003. PMID: 12973100

6

Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience.

Jordan SC, Vo AA, Nast CC, Tyan D. Jordan SC, et al. Among authors: vo aa. Clin Transpl. 2003:193-8. Clin Transpl. 2003. PMID: 15387111 Review.

7

Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.

Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J. Jordan SC, et al. J Am Soc Nephrol. 2004 Dec;15(12):3256-62. doi: 10.1097/01.ASN.0000145878.92906.9F. J Am Soc Nephrol. 2004. PMID: 15579530 Clinical Trial.

8

Cyclosporine-sparing effects of daclizumab in renal allograft recipients.

Ingle GR, Moudgil A, Vo A, Jordan SC. Ingle GR, et al. Am J Health Syst Pharm. 2005 Feb 15;62(4):391-6. doi: 10.1093/ajhp/62.4.0391. Am J Health Syst Pharm. 2005. PMID: 15745891 Clinical Trial.

9

Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection.

Jordan SC, Vo AA, Toyoda M, Tyan D, Nast CC. Jordan SC, et al. Among authors: vo aa. Pediatr Transplant. 2005 Apr;9(2):155-61. doi: 10.1111/j.1399-3046.2005.00256.x. Pediatr Transplant. 2005. PMID: 15787786 Review.

10

Current approaches to treatment of antibody-mediated rejection.

Jordan SC, Vo AA, Tyan D, Nast CC, Toyoda M. Jordan SC, et al. Among authors: vo aa. Pediatr Transplant. 2005 Jun;9(3):408-15. doi: 10.1111/j.1399-3046.2005.00363.x. Pediatr Transplant. 2005. PMID: 15910400 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

125 results

Search Page

Filters